

Presentation at The Lancet Summit on GeNeuro's Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

- Dr. Hervé Perron, Chief Scientific Officer, presented at “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the joint NINDS/GeNeuro Amyotrophic lateral sclerosis (ALS) preclinical research program
- Results confirm the efficacy of GeNeuro's novel anti-HERV-K monoclonal antibody against HERV-K-ENV mediated neurotoxicity

Geneva, Switzerland, 20 December, 2021 – 7.30 am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH).

“This joint NINDS/GeNeuro study has shown the specific and efficient inhibition of HERV-K ENV neurotoxic effects from the extracellular medium in vitro and in vivo, using GeNeuro's anti HERV-K K01 monoclonal antibody,” said **Dr. Hervé Perron, Chief Scientific Officer of GeNeuro.**

“A new pathogenic mechanism has been unveiled and characterized, and these results open new perspectives for a therapeutic intervention against sporadic ALS,” said **Dr. Avindra Nath, Clinical Director at the National Institute of Neurological Disorders and Stroke**, who leads the joint NINDS/GeNeuro ALS research program.

These results, following those presented by Dr. Avindra Nath at the American Neurological Association (ANA) annual meeting on October 17, 2021, show in vitro and in vivo the neurotoxic effects specifically mediated by HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses (HERV-K ENV protein). More importantly, they confirm the neutralizing effects of GeNeuro's novel specific monoclonal anti-HERV-K antibody.

As previously mentioned, GeNeuro's preclinical development program has enabled its anti-HERV-K ENV antibody to now be humanized and ready to enter GMP manufacturing. The program could start clinical trials as early as 2022.

“These results confirm the potentially key role of HERV-K ENV in ALS and the potential of GeNeuro's new antibody in this indication,” said **Jesús Martín-García, CEO of GeNeuro.** *“We will now seek partnerships to bring this product to patients as rapidly as possible.”*

The presentation is available on GeNeuro's [YouTube](#) channel.

About ALS

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease or clinically as motor neuron disease, is a fatal, rapidly progressive neurodegenerative disease characterized by loss of motor neurons leading to progressive muscular paralysis. The incidence of ALS is approximately 5 per 100,000 individuals in the USA, 1-3 per 100,000 individuals worldwide, and is consistent across diverse populations.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com



Contacts:

GeNeuro

Jesús Martin-Garcia

Chairman and CEO
+41 22 552 4800
investors@geneuro.com

NewCap

Louis-Victor Delouvrier / Mathilde Bohin (investors)

+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 94 98
geneuro@newcap.eu

Disclaimer:

This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.